文献速递肿瘤 PET/CT神经核医学

双硼硼氨基酸PET示踪剂用于脑肿瘤诊断

A bis-boron boramino acid PET tracer for brain tumor diagnosis.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2024-01-09

本研究报道了三氟硼酸衍生的硼苯丙氨酸(BBPA)作为PET示踪剂用于肿瘤成像。在胶质瘤和脑转移瘤患者中,[18F]BBPA-PET显示良好的肿瘤摄取,肿瘤与正常脑比值(T/N比)为18.7 ± 5.5(n = 11),高于常见氨基酸PET示踪剂。定量参数在不同强化状态下无差异(P = 0.115-0.687),提示[18F]BBPA摄取独立于MRI增强。

要点

  • 癌细胞竞争抑制实验提示[18F]BBPA的细胞蓄积通过大中性氨基酸转运体1型(LAT-1)介导。
  • 在B16-F10荷瘤小鼠中[18F]BBPA显示显著肿瘤摄取,为泛癌种探针。
  • 胶质瘤和脑转移瘤患者中[18F]BBPA-PET的T/N比为18.7 ± 5.5(n = 11),高于常见氨基酸PET示踪剂。

核心结论

  • 本研究概述了一项[18F]BBPA临床试验,以实现PET更高的肿瘤特异性蓄积,为脑肿瘤诊断提供潜在技术,并可能促进脑肿瘤的硼中子俘获治疗(BNCT)。

研究设计与样本

  • 本研究报道了三氟硼酸衍生的硼苯丙氨酸(BBPA),其为用于BNCT的硼苯丙氨酸(BPA)的衍生物,作为有前景的肿瘤成像PET示踪剂。

主要发现

  • 癌细胞竞争抑制实验提示[18F]BBPA的细胞蓄积通过大中性氨基酸转运体1型(LAT-1)介导。
  • [18F]BBPA为泛癌种探针,在B16-F10荷瘤小鼠中显示显著肿瘤摄取。
  • 胶质瘤和脑转移瘤患者中[18F]BBPA-PET显示良好肿瘤摄取和显著的肿瘤与正常脑比值(T/N比,18.7 ± 5.5,n = 11),高于常见氨基酸PET示踪剂。
  • [18F]BBPA-PET定量参数在不同强化状态间无差异(P = 0.115-0.687),提示[18F]BBPA摄取独立于MRI增强。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Boramino acids are a class of amino acid biomimics that replace the carboxylate group with trifluoroborate and can achieve the 18F-labeled positron emission tomography (PET) and boron neutron capture therapy (BNCT) with identical chemical structure. METHODS: This study reports a trifluoroborate-derived boronophenylalanine (BBPA), a derived boronophenylalanine (BPA) for BNCT, as a promising PET tracer for tumor imaging. RESULTS: Competition inhibition assays in cancer cells suggested the cell accumulation of [18F]BBPA is through large neutral amino acid transporter type-1 (LAT-1). Of note, [18F]BBPA is a pan-cancer probe that shows notable tumor uptake in B16-F10 tumor-bearing mice. In the patients with gliomas and metastatic brain tumors, [18F]BBPA-PET shows good tumor uptake and notable tumor-to-normal brain ratio (T/N ratio, 18.7 ± 5.5, n = 11), higher than common amino acid PET tracers. The [18F]BBPA-PET quantitative parameters exhibited no difference in diverse contrast-enhanced status (P = 0.115-0.687) suggesting the [18F]BBPA uptake was independent from MRI contrast-enhancement. CONCLUSION: This study outlines a clinical trial with [18F]BBPA to achieve higher tumor-specific accumulation for PET, provides a potential technique for brain tumor diagnosis, and might facilitate the BNCT of brain tumors.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Li Z, Chen J, Kong Z, et al. A bis-boron boramino acid PET tracer for brain tumor diagnosis. Eur J Nucl Med Mol Imaging. 2024. PMID: 38191817. doi:10.1007/s00259-024-06600-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。